Recent studies show that endemic hepatitis E virus (HEV) infection occurs frequently in some developed countries. In the Netherlands in 2013, the routine screening of 35,220 plasma donations for HEV RNA showed 20 donors to be viremic (1:1761), which seems to contradict reports of declining HEV seroprevalence in the recent past.
R
ecently it became clear that indigenous infection with hepatitis E virus (HEV) Genotype 3 is common in some industrialized countries. 1, 2 Although the transmission routes are not well understood, domesticated swine are a likely source of infection. 3 In the Netherlands pig farming is very intensive, with 12,000,000 piglets being reared each year. Among Dutch blood donors, a low anti-HEV seroprevalence of 0.4% was reported in 1993, determined using experimental HEV antibody screening and confirmatory assays from Abbott Laboratories (Chicago, IL) and Diagnostic Biotechnology (DB, Singapore). 4 A more recent study reported 1.9% of the Dutch population to be confirmed anti-HEV positive in 2007, using an enzyme immunoassay (EIA; MP Diagnostics, Santa Ana, CA). 5 The assays used in these studies are not the most sensitive HEV IgG tests, in particular for detecting past infection with HEV Genotype 3. 6 More sensitive, validated HEV antibody tests have become available. 7 We reported a strikingly higher seroprevalence of 27% among Dutch blood donors in 2011, employing an anti-HEV IgG EIA (Wantai Biological ABBREVIATION: OD/CO = optical density divided by cutoff value.
Pharmacy Enterprise Co., Ltd, Beijing, China). 8 The seroprevalence increased strongly with age, which could be indicative of an age cohort effect. An age cohort effect results in a higher seroprevalence in older persons, not (only) because of age-dependent cumulative exposure, but because infection pressure was higher in the past. Indeed an age cohort effect has been demonstrated in the United Kingdom, Denmark, and the United States. [9] [10] [11] Our previous study suggested a high incidence of HEV infection of 1.1% per person-year between 2009 and 2011. In 2013, the routine screening of 3000 Dutch plasma donations each month, in pools of 96, showed 20 of 35,220 donors (1 in 1761) to be viremic (data not shown). Assuming that the higher anti-HEV seroprevalence in donors older than 40 is caused by an age cohort effect, the recent high incidence suggests strong fluctuations of HEV infection pressure over time. To assess the prevalence of HEV infection in the past we studied archived donor plasma samples collected in the years 1988 to 2004 and compared the results with recent findings among donors in 2011.
MATERIALS AND METHODS

Repository samples
The repository sample archive consists of over more than 
Sample selection
Samples of donations from 1988 and from 2000 were retrieved for HEV antibody testing. For each year of birth at least 10 donors were sampled, for 1988 and for 2000. Because the retrieval of specific samples from 1.5 million frozen samples is very labor intensive, the following approach was adopted. First, all donations in a set of random archive plates, containing donations from 1988 and from 2000, were tested. Subsequently, to compensate for the distribution of donor age, additional donations were retrieved and tested, to obtain at least 10 tested donors for each year of birth. 
HEV antibody testing
Samples were tested using an anti-HEV IgG assay (Wantai Biological Pharmacy Enterprise Co., Ltd) according to the manufacturer's instructions. Recently this assay has been validated and compared to other anti-HEV assays. 7 Borderline reactive samples (optical density/cutoff [OD/ CO] > 0.9 and < 1.1) were considered negative. Results were compared with those from our previous study in which the anti-HEV IgG prevalence was determined in 5329 donor samples, collected on 2 days in March 2011 in all Dutch blood collection centers. 8 Prolonged sample storage may cause increased nonspecific reactivity in antibody assays. 12 To investigate this issue the distribution of the signal strength in samples of 1988, 2000, and 2011 was compared. The persistence of anti-HEV IgG levels over a 22-year period was investigated by testing serial samples of 23 donors who tested positive in 1988.
Statistical analysis
Statistical significance was calculated using the chisquare test. The Newcombe-Wilson method was applied to determine 95% confidence intervals (CIs). 
RESULTS
DISCUSSION
The anti-HEV seroprevalence has been shown to differ in western countries. Part of the variation is due to the use of different HEV IgG assays. 3 Recent studies, with sensitive assays, showed seroprevalences among blood donors of 16% in the United States and in southwest England, 17% in Germany, 21% in Denmark, 27% in the Netherlands, and 52% in the southwest of France. 6, 8, 10, 11, 13, 14 The anti-HEV seroprevalence invariably increases with age. In England, Denmark, and the United States the testing of archived samples showed that the seroprevalence declined in recent decades. [9] [10] [11] In the Netherlands HEV seroprevalence also declined over time. Hence the age-related seroprevalence seems largely caused by decreased infection pressure, not by variability in acquiring infection in the course of life. Nevertheless, currently at least one acutely infected Dutch donor donates each day. 8 Our findings provide an explanatory scenario. Decades ago, HEV infection pressure was very high and most people acquired infection. Subsequently a prolonged period of low incidence occurred, causing the age cohort effect. Recently the incidence of HEV infection increased again, as illustrated by the increasing seroprevalence after 2000 among blood donors aged 18 to 21 and the frequent finding of viremic donors.
Conclusions about the dynamics of HEV infection can only be drawn if the IgG anti-HEV response is detected reliably over time, in terms of both sensitivity and specificity. Our longitudinal data show that, employing the Wantai assay, anti-HEV IgG responses are detected consistently over time and seroprevalence seems a reliable indicator for cumulative HEV infection in the past. The use of a sensitive screening test is hampered by the unavailability of an equally sensitive, more specific confirmatory test. Probably some donors tested false positive. We showed that long-term storage did not cause nonspecific reactivity. The current study is limited to samples collected in the western part of the Netherlands. Previously we demonstrated that the regional variation of HEV seroprevalence in the Netherlands is neglectible. 8 The source and transmission routes of current autochthonous HEV infection in Europe are unknown; domesticated swine probably play a role. 15 In the Netherlands in 2005, 55% of pooled stool samples from pigs tested positive for HEV RNA, 16 showing the same HEV-3 subtypes as found among Dutch blood donors. 8 The cause of the decline and reemergence of HEV in recent decades is enigmatic. The source and the genotype of HEV strains that caused the high seroprevalence in the 1980s is unknown; it cannot be ruled out that the seroreactivity is the result of cross-reacting antibodies against an unknown HEV-like virus.
HEV transmission by blood transfusion has been reported in various countries. [17] [18] [19] The recent high incidence of HEV infection may be less than before 1988, when anti-HEV seroprevalence among the oldest donors reached 76%. In hindsight, some cases of posttransfusion non-A, non-B hepatitis in those days may have been caused by HEV, not by hepatitis C virus. HEV transmission may be a threat to the safety of blood, especially if immunosuppressed recipients are considered. To our knowledge, universal donor screening for HEV is only performed in some areas of Japan. Because of the high incidence of community-acquired HEV infection, the screening of blood donors for HEV will only prevent part of HEV infections among vulnerable patients. Irrespective of donor screening for HEV, certain immunosuppressed patients should be monitored for HEV infection. At present, the elucidation of the transmission routes in communityacquired HEV infection, enabling the institution of control measures, seems more relevant than the introduction of blood donor screening for HEV. 
